Jazz Pharmaceuticals (JAZZ) PT Raised to $176 at Morgan Stanley on Xyrem and Xywav

Morgan Stanley analyst David Risinger raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $176.00 (from $162.00) on expected Xywav upside and the GW acquisition (expected to close in 2Q).

The analyst maintained an Overweight rating, stating "Jazz's conversion of Xyrem to Xywav is likely to be faster than anticipated, and the planned acquisition of GW Pharma (expected to close in 2Q) adds durable long-term growth to Jazz's portfolio. GW's key asset Epidiolex appears set for continued strong growth given its approval in three seizure types and potential for off-label use, and Epidiolex is unlikely to face generic competition until the mid-2030's."

You May Also Be Interested In

• Cowen's Conviction on Jazz Pharmaceuticals (JAZZ) 'Growing Stronger', Buy on Weakness
• Osisko Gold Royalties Ltd. (OR:CN) (OR) PT Raised to Cdn$23 at Stifel Canada
• S4 Capital Plc. (SFOR:LN) PT Raised to GBP6.70 at Jefferies